Compare Becton Dickinson and Co (BDX) vs ConocoPhillips (COP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs ConocoPhillips — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while ConocoPhillips trades at $126.3 (market cap $147.80B). The key difference: ConocoPhillips is far larger — about 3× Becton Dickinson and Co's market cap, and ConocoPhillips pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| BDX | COP | |
|---|---|---|
Market Cap | $48.93B | $147.80B |
Sector | Health | Energy |
52-Week High | $185.39 | $133.80 |
52-Week Low | $138.62 | $85.66 |
Enterprise Value | $65.03B | $163.40B |
Dividend Yield | 2.34% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
ConocoPhillips (COP) trades at $117.61, up 0.73% today, with a bullish technical signal from moving averages and a consensus analyst price target of $149.25. Recent Q2 2026 earnings beat expectations with EPS of $3.24 versus $2.90 estimated, driven by strong Permian Basin output and higher oil prices. The company reaffirmed its $7 billion free cash flow target by 2029 and completed a $1.7 billion asset sale ahead of schedule.
Outlook is positive due to robust operational performance and favorable oil market trends, but risks include commodity price volatility and CEO transition. The stock offers value with a P/E of 15.56 and a net income margin of 14.65%, supported by 74.51% analyst buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →
